A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Sponsor
Aragon Pharmaceuticals, Inc. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT02123758
Collaborator
(none)
57
Enrollment
7
Locations
2
Arms
99.2
Anticipated Duration (Months)
8.1
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Condition or DiseaseIntervention/TreatmentPhase
Phase 1

Detailed Description

This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will take abiraterone acetate + prednisone [AAP] once daily on Days 1-7 of Treatment Cycle 1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment Cycle 1, Day 8 through to the end of treatment [ie, for up to an expected duration of approximately 18 months] and will be conducted as two cohorts (group of participant's). The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA). Participant safety will also be monitored by the collection of adverse events. Imaging assessments for disease evaluation will be planned at discretion of the Investigator. Once all participants have completed study treatment up to Cycle 3 Day 1, a data cutoff is planned to evaluate the short term safety profile of the combination and to complete the PK analysis up to the cutoff date. All participants will continue on study (ie, to receive treatment) until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. The end of the study is defined when all participants have completed treatment. Participant's safety will be monitored throughout the study.

Study Design

Study Type:
Interventional
Actual Enrollment :
57 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer
Actual Study Start Date :
Jul 9, 2014
Actual Primary Completion Date :
Jun 27, 2016
Anticipated Study Completion Date :
Oct 15, 2022

Arms and Interventions

ArmIntervention/Treatment
Experimental: Cohort 1

Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.

Drug: Abiraterone Acetate
Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
Other Names:
  • ZYTIGA
  • Drug: Prednisone
    Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

    Drug: JNJ-56021927
    Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

    Experimental: Cohort 2

    Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.

    Drug: Abiraterone Acetate
    Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
    Other Names:
  • ZYTIGA
  • Drug: Prednisone
    Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

    Drug: JNJ-56021927
    Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

    Outcome Measures

    Primary Outcome Measures

    1. Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of abiraterone [Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)]

      The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.

    2. Maximum plasma concentration (Cmax) of abiraterone, prednisone and its metabolite prednisolone [Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)]

      The Cmax is the maximum observed plasma concentration.

    3. Area Under the Plasma Concentration-time Curve From Time Zero to Time 12 Hours (AUC [0-12]) of prednisone and its metabolite prednisolone [Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)]

      The AUC (0-12) is area under the plasma concentration-time curve from time zero to time 12 hours.

    Secondary Outcome Measures

    1. Area Under the Plasma Concentration Curve (AUC [0- 24h]) of JNJ-56021927 and its metabolite JNJ-56142060 [Day 36 (Treatment Cycle 2), on Day 57 (Treatment Cycle 3)]

      The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.

    2. Maximum plasma concentration (Cmax) of JNJ-56021927 and its metabolite JNJ-56142060 [Day 36 (Treatment Cycle 2), on Day 57 (Treatment Cycle 3)]

      The Cmax is the maximum observed plasma concentration.

    3. Change in prostate specific antigen (PSA) [Up to the end of the treatment phase (approximately 18 months)]

      Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.

    4. Maximal decline in prostate specific antigen (PSA) [Up to the end of the treatment phase (approximately 18 months)]

      Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to (<=) 2

    • Histologically or cytologically confirmed adenocarcinoma of the prostate

    • Documentation of metastatic disease

    • Prostate cancer progression

    • Surgically or medically castrated, with testosterone levels of less than (<) 50 nanogram per deciliter (ng/dL)

    • Adequate bone marrow and organ function

    Exclusion Criteria:
    • Known brain metastases

    • Pathological finding consistent with small cell carcinoma of the prostate

    • Administration of an investigational agent within 4 weeks of Treatment Cycle 1, Day 1

    • Chemotherapy, or immunotherapy for the treatment of prostate cancer within 4 weeks of Treatment Cycle 1, Day 1

    • Therapies that must be discontinued or substituted prior to Treatment Cycle 1, Day 1 include the following: Medications known to lower the seizure threshold; Herbal and non-herbal products that may decrease prostate specific antigen (PSA) levels (that is, saw palmetto, pomegranates or pomegranate juice); Medications known to induce drug metabolizing enzymes such as dexamethasone, rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's wort, etc.; and, potent inhibitors of CYP3A4 or CYP2C8

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Los AngelesCaliforniaUnited States
    2San FranciscoCaliforniaUnited States
    3HoustonTexasUnited States
    4VancouverBritish ColumbiaCanada
    5MontrealQuebecCanada
    6RotterdamNetherlands
    7SuttonUnited Kingdom

    Sponsors and Collaborators

    • Aragon Pharmaceuticals, Inc.

    Investigators

    • Study Director: Aragon Pharmaceuticals, Inc. Clinical Trial, Aragon Pharmaceuticals, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Aragon Pharmaceuticals, Inc.
    ClinicalTrials.gov Identifier:
    NCT02123758
    Other Study ID Numbers:
    • CR104358
    • 56021927PCR1010
    • 2014-001426-14
    First Posted:
    Apr 28, 2014
    Last Update Posted:
    Dec 3, 2021
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Aragon Pharmaceuticals, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 3, 2021